← All trials
NCT04904120
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 5, 2021
- Primary completion
- Jul 16, 2022
- Completion date
- Jul 16, 2022
- First posted
- May 27, 2021
- Last posted
- May 27, 2021
- Enrollment
- 10
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Viewpoint Molecular TargetingLead sponsor
- Mayo ClinicCollaborator
- Mayo ClinicOverall official - principal investigator
- Viewpoint Molecular TargetingOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.